Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label Study to Assess the Pharmacokinetics and Relative Bioavailability of AZD4635 in Non-Smoking Healthy Male Subjects, With the Option to Assess Food Effect, pH Effect and Absolute Bioavailability

Next Previous
Trial Profile

A Phase I, Open-Label Study to Assess the Pharmacokinetics and Relative Bioavailability of AZD4635 in Non-Smoking Healthy Male Subjects, With the Option to Assess Food Effect, pH Effect and Absolute Bioavailability

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imaradenant (Primary) ; Imaradenant (Primary) ; Lansoprazole
  • Indications Cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Acronyms Rel Bio
  • Sponsors AstraZeneca

Most Recent Events

  • 13 Apr 2023 Results reporting PK and safety from two phase 1 clinical studies (D8730C00007 and D8730C00002) published in the British Journal of Clinical Pharmacology
  • 24 Jun 2020 Results, pooled analysis of data form two phase I studies (Phase 1 Study in healthy volunteers (N=20) and another study in Cancer patients (N=121)), assessing pharmacokinetics results to provide dosing and formulation recommendation, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
  • 10 Apr 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top